Evidence map›Paper›PMID 38957915›Full record

ArticlePhysical chemistry chemical physics : PCCP2024

Valence photoelectron imaging of molecular oxybenzone.

Svetlana Tsizin, Loren Ban, Egor Chasovskikh, Bruce L Yoder, Ruth Signorell

Abstract read
In one paragraph

Article in Physical chemistry chemical physics : PCCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Svetlana TsizinDepartment of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 2., CH-8093 Zürich, Switzerland. stsizin@ethz.ch.ORCID http://orcid.org/0000-0002-1250-9598
Loren BanDepartment of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 2., CH-8093 Zürich, Switzerland. stsizin@ethz.ch.ORCID http://orcid.org/0000-0002-9312-2984
Egor ChasovskikhDepartment of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 2., CH-8093 Zürich, Switzerland. stsizin@ethz.ch.
Bruce L YoderDepartment of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 2., CH-8093 Zürich, Switzerland. stsizin@ethz.ch.
Ruth SignorellDepartment of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 2., CH-8093 Zürich, Switzerland. stsizin@ethz.ch.ORCID http://orcid.org/0000-0003-1111-9261

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An oxybenzone molecule in the gas phase was characterized by mass spectrometry and angle-resolved photoelectron spectroscopy, using both single and multiphoton ionization schemes. A tabletop high harmonic generation source with a monochromator was used for single-photon ionization of oxybenzone with photon energies of up to 35.7 eV. From this, vertical ionization and appearance energies, as well as energy-dependent anisotropy parameters were retrieved and compared with the results from DFT calculations. For two-photon ionization using 4.7 eV light, we found a higher appearance energy than in the extreme ultraviolet (EUV) case, highlighting the possible influence of an intermediate state on the photoionization process. We found no differences in the mass spectra when ionizing oxybenzone by single-photons between 17.2 and 35.7 eV. However, for the multiphoton ionization, the fragmentation process was found to be sensitive to the photoionization order and laser intensity. The "softest" method was found to be two-photon ionization using 4.7 eV light, which led to no measurable fragmentation up to an intensity of 5 × 10

Identifiers

PMID38957915
PMCPMC11253247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.